DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

20152,166 citationsJournal Articlebronze Open Access

Authors

Joaquı́n Mateo · Royal Marsden NHS Foundation Trust

Suzanne Carreira

Shahneen Sandhu · Royal Marsden NHS Foundation Trust

Susana Miranda

Helen Mossop

Raquel Pérez-López · Royal Marsden NHS Foundation Trust

Daniel Nava Rodrigues

Dan R. Robinson · University of Michigan–Ann Arbor

Aurelius Omlin

Abstract

Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. (Funded by Cancer Research UK and others; ClinicalTrials.gov number, NCT01682772; Cancer Research UK number, CRUK/11/029.).

Topics & Keywords

PARP inhibition in cancer therapy Prostate Cancer Treatment and Research Cell death mechanisms and regulation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 18, pp. 1697-1708

DOI: 10.1056/nejmoa1506859

Field-Weighted Citation Impact: 100.26